- Title
- Restoring microvascular circulation with diagnostic ultrasound and contrast agent: rationale and design of the REDUCE trial
- Creator
- Jeyaprakash, Prajith; Pathan, Faraz; Boyle, Andrew; Ford, Thomas J.; Porter, Thomas R.; Negishi, Kazuaki; Ozawa, Koya; Robledo, Kristy P.; Shah, Karan K.; Morton, Rachael L.; Yu, Christopher; Madronio, Christine; Hallani, Hisham; Loh, Han
- Relation
- American Heart Journal Vol. 275, Issue September 2024, p. 163-172
- Publisher Link
- http://dx.doi.org/10.1016/j.ahj.2024.06.008
- Publisher
- Mosby
- Resource Type
- journal article
- Date
- 2024
- Description
- Objectives: This study aims to evaluate the efficacy and cost-effectiveness of sonothrombolysis delivered pre and post primary percutaneous coronary intervention (pPCI) on infarct size assessed by cardiac MRI, in patients presenting with STEMI, when compared against sham procedure. Background: More than a half of patients with successful pPCI have significant microvascular obstruction and residual infarction. Sonothrombolysis is a therapeutic use of ultrasound with contrast enhancement that may improve microcirculation and infarct size. The benefits and real time physiological effects of sonothrombolysis in a multicentre setting are unclear. Methods: The REDUCE (Restoring microvascular circulation with diagnostic ultrasound and contrast agent) trial is a prospective, multicentre, patient and outcome blinded, sham-controlled trial. Patients presenting with STEMI will be randomized to one of 2 treatment arms, to receive either sonothrombolysis treatment or sham echocardiography before and after pPCI. This tailored design is based on preliminary pilot data from our centre, showing that sonothrombolysis can be safely delivered, without prolonging door to balloon time. Our primary endpoint will be infarct size assessed on day 4±2 on Cardiac Magnetic Resonance (CMR). Patients will be followed up for 6 months post pPCI to assess secondary endpoints. Sample size calculations indicate we will need 150 patients recruited in total. Conclusions: This multicentre trial will test whether sonothrombolysis delivered pre and post primary PCI can improve patient outcomes and is cost-effective, when compared with sham ultrasound delivered with primary PCI. The results from this trial may provide evidence for the utilization of sonothrombolysis as an adjunct therapy to pPCI to improve cardiovascular outcomes in STEMI. ANZ Clinical Trial Registration number: ACTRN 12620000807954.
- Subject
- primary percutaneous coronary intervention (pPCI); cardiac MRI; microvascular circulation; patient outcomes
- Identifier
- http://hdl.handle.net/1959.13/1508965
- Identifier
- uon:56177
- Identifier
- ISSN:0002-8703
- Rights
- x
- Language
- eng
- Reviewed
- Hits: 898
- Visitors: 896
- Downloads: 0